相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan et al.
NATURE MEDICINE (2022)
Conserved topology of virus glycoepitopes presents novel targets for repurposing HIV antibody 2G12
Nathaniel L. Miller et al.
SCIENTIFIC REPORTS (2022)
The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa
Yuki Yamaguchi et al.
MABS (2022)
Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
Emi Takashita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
On-target IgG hexamerisation driven by a C-terminal IgM tail-piece fusion variant confers augmented complement activation
Joshua M. Sopp et al.
COMMUNICATIONS BIOLOGY (2021)
Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
Alexandra Schafer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection
Myron S. Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler et al.
CELL (2021)
New INN nomenclature for monoclonal antibodies
Raffaella Balocco et al.
LANCET (2021)
A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus
Bronwyn M. Gunn et al.
IMMUNITY (2021)
Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET
Joost Neijssen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis
Dana L. E. Vergoossen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Dapeng Li et al.
CELL (2021)
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Irfan Ullah et al.
IMMUNITY (2021)
Considerations for the Design of Antibody-Based Therapeutics
Dennis R. Goulet et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Concepts for agonistic targeting of CD40 in immuno-oncology
David M. Richards et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors
Dennis R. Goulet et al.
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS (2020)
Weak Fragment Crystallizable (Fc) Domain Interactions Drive the Dynamic Assembly of IgG Oligomers upon Antigen Recognition
Juergen Strasser et al.
ACS NANO (2020)
Structural and immunogenomic insights into B-cell receptor activation
Yangyang Feng et al.
JOURNAL OF GENETICS AND GENOMICS (2020)
Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab
Lionel Rouge et al.
SCIENCE (2020)
Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation
Sylwia Jones et al.
SCIENTIFIC REPORTS (2020)
DuoHexaBody-CD37(R), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
Simone C. Oostindie et al.
BLOOD CANCER JOURNAL (2020)
Multispecific drugs herald a new era of biopharmaceutical innovation
Raymond J. Deshaies
NATURE (2020)
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Potently neutralizing and protective human antibodies against SARS-CoV-2
Seth J. Zost et al.
NATURE (2020)
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Alina Baum et al.
SCIENCE (2020)
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Johanna Hansen et al.
SCIENCE (2020)
Dual Epitope Targeting and Enhanced Hexamerization by DR5 Antibodies as a Novel Approach to Induce Potent Antitumor Activity Through DR5 Agonism
Marije B. Overdijk et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
Stylianos Bournazos et al.
NATURE (2020)
Binding mechanisms of therapeutic antibodies to human CD20
Anand Kumar et al.
SCIENCE (2020)
REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters
Alina Baum et al.
SCIENCE (2020)
A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms
James E. Stefano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response
Roeland Lameris et al.
NATURE CANCER (2020)
Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
Geert van Tetering et al.
ANTIBODIES (2020)
Structure, Function, and Therapeutic Use of IgM Antibodies
Bruce A. Keyt et al.
ANTIBODIES (2020)
Targeted IgMs agonize ocular targets with extended vitreal exposure
Yvonne Chen et al.
MABS (2020)
Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats
Ami Miller et al.
MABS (2020)
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
Mitchell Evers et al.
MABS (2020)
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Lan Wu et al.
NATURE CANCER (2020)
Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets
Maaike Rijkers et al.
HAEMATOLOGICA (2019)
CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering
Simone C. Oostindie et al.
HAEMATOLOGICA (2019)
Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma
Thomas A. Ollila et al.
ONCOTARGETS AND THERAPY (2019)
Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members
Yanli Yang et al.
MABS (2019)
Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces
Juergen Strasser et al.
NANO LETTERS (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Insights into IgM-mediated complement activation based on in situ structures of IgM-C1-C4b
Thomas H. Sharp et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
The Neonatal Fc Receptor (FcRn): A Misnomer?
Michal Pyzik et al.
FRONTIERS IN IMMUNOLOGY (2019)
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG
Arianne M. Brandsma et al.
FRONTIERS IN IMMUNOLOGY (2019)
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
David M. Richards et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism
Ulrich F. Prodjinotho et al.
PARASITOLOGY RESEARCH (2019)
Redirected T Cell Cytotoxicity in Cancer Therapy
Raphael A. Clynes et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection
Anna Z. Wec et al.
CELL HOST & MICROBE (2019)
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Sabue Mulangu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Molecular recognition of the native HIV-1 MPER revealed by STED microscopy of single virions
Pablo Carravilla et al.
NATURE COMMUNICATIONS (2019)
Structural basis for cooperativity of human monoclonal antibodies to meningococcal factor H-binding protein
Ilaria Peschiera et al.
COMMUNICATIONS BIOLOGY (2019)
Multiple Variables at the Leukocyte Cell Surface Impact Fc γ Receptor-Dependent Mechanisms
Kashyap R. Patel et al.
FRONTIERS IN IMMUNOLOGY (2019)
Antibody Structure and Function: The Basis for Engineering Therapeutics
Mark L. Chiu et al.
ANTIBODIES (2019)
IgE Antibodies: From Structure to Function and Clinical Translation
Brian J. Sutton et al.
ANTIBODIES (2019)
IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
Annelot Breedveld et al.
FRONTIERS IN IMMUNOLOGY (2019)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates
Kristen E. Pascal et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement
Deniz Ugurlar et al.
SCIENCE (2018)
Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope
Katharina Imkeller et al.
SCIENCE (2018)
Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
James J. Steinhardt et al.
NATURE COMMUNICATIONS (2018)
Neutrophils Kill Antibody-Opsonized Cancer Cells by Trogoptosis
Hanke L. Matlung et al.
CELL REPORTS (2018)
Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways
Gina-Maria Lilienthal et al.
FRONTIERS IN IMMUNOLOGY (2018)
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses A Phase 2 Randomized Clinical Trial
Clara Montagut et al.
JAMA ONCOLOGY (2018)
A Single-Agent Dual-Specificity Targeting of FOLR1 and DR5 as an Effective Strategy for Ovarian Cancer
Gururaj Shivange et al.
CANCER CELL (2018)
Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Sijia Huang et al.
MABS (2018)
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
Meinolf Thiemann et al.
FRONTIERS IN ONCOLOGY (2018)
The immune response against flaviviruses
Jose Luis Slon Campos et al.
NATURE IMMUNOLOGY (2018)
CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells
Kerstin Schuetze et al.
FRONTIERS IN IMMUNOLOGY (2018)
CD32 Ligation Promotes the Activation of CD4(+) T Cells
Maria Pia Holgado et al.
FRONTIERS IN IMMUNOLOGY (2018)
The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein
Emiri Hiramoto et al.
SCIENCE ADVANCES (2018)
Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts
David Oyen et al.
SCIENCE ADVANCES (2018)
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells
Christian Merz et al.
JOURNAL OF IMMUNOTHERAPY (2018)
Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions
Tania F. Rowley et al.
COMMUNICATIONS BIOLOGY (2018)
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Kensei Tobinai et al.
ADVANCES IN THERAPY (2017)
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
Katharine D. Grugan et al.
MABS (2017)
Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells
Annalina Tammen et al.
JOURNAL OF IMMUNOLOGY (2017)
Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization
Di Zhang et al.
MABS (2017)
IgG cooperativity - Is there allostery? Implications for antibody functions and therapeutic antibody development
Danlin Yang et al.
MABS (2017)
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms
Michael M. Grandal et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Human Secretory IgM Antibodies Activate Human Complement and Offer Protection at Mucosal Surface
T. E. Michaelsen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2017)
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Ling Xu et al.
SCIENCE (2017)
IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity
Taia T. Wang et al.
SCIENCE (2017)
Structural basis of a novel heterodimeric Fc for bispecific antibody production
Hudie Wei et al.
ONCOTARGET (2017)
Improvement of Pharmacokinetic Profile of TRAIL via Trimer-Tag Enhances its Antitumor Activity in vivo
Haipeng Liu et al.
SCIENTIFIC REPORTS (2017)
Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy
Silvia von Karstedt et al.
NATURE REVIEWS CANCER (2017)
Anti-CD20 Antibody with Multimerized Fc Domains: A Novel Strategy To Deplete B Cells and Augment Treatment of Autoimmune Disease
Xiaoyu Zhang et al.
JOURNAL OF IMMUNOLOGY (2016)
Onto better TRAILs for cancer treatment
D. de Miguel et al.
CELL DEATH AND DIFFERENTIATION (2016)
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Francisco J. Sanchez-Martin et al.
CLINICAL CANCER RESEARCH (2016)
Harnessing Fc receptor biology in the design of therapeutic antibodies
Peter Sondermann et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?
Janine Schuurman et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody
Di Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
A Modeling and Experimental Investigation of the Effects of Antigen Density, Binding Affinity, and Antigen Expression Ratio on Bispecific Antibody Binding to Cell Surface Targets
John J. Rhoden et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Katelyn T. Byrne et al.
JOURNAL OF IMMUNOLOGY (2016)
Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions
Erika M. Cook et al.
JOURNAL OF IMMUNOLOGY (2016)
Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody
Songmao Zheng et al.
MABS (2016)
Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen
Guanbo Wang et al.
MOLECULAR CELL (2016)
Control of B Cell Responsiveness by Isotype and Structural Elements of the Antigen Receptor
Elias Hobeika et al.
TRENDS IN IMMUNOLOGY (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo
Xiuhong Piao et al.
ONCOIMMUNOLOGY (2016)
Enhancement of Immune Effector Functions by Modulating IgG's Intrinsic Affinity for Target Antigen
Yariv Mazor et al.
PLOS ONE (2016)
Phagocytosis of immunoglobulin-coated emulsion droplets
Kalthoum Ben M'Barek et al.
BIOMATERIALS (2015)
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic NanobodyA® targeting the DR5 receptor
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect
David J. DiLillo et al.
CELL (2015)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Mouse and human FcR effector functions
Pierre Bruhns et al.
IMMUNOLOGICAL REVIEWS (2015)
A single glycan on IgE is indispensable for initiation of anaphylaxis
Kai-Ting C. Shade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering
Yuki Iwayanagi et al.
JOURNAL OF IMMUNOLOGY (2015)
IgA as therapeutic antibody
Jeanette H. W. Leusen
MOLECULAR IMMUNOLOGY (2015)
Complement in therapy and disease Regulating the complement system with antibody-based therapeutics
Joost P. M. Melis et al.
MOLECULAR IMMUNOLOGY (2015)
Responsiveness of B cells is regulated by the hinge region of IgD
Rudolf Uebelhart et al.
NATURE IMMUNOLOGY (2015)
A prominent lack of IgG1-Fc fucosylation of platelet alloantibodies in pregnancy
Rick Kapur et al.
BLOOD (2014)
Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
Stylianos Bournazos et al.
CELL (2014)
Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer
Saskia Meyer et al.
MABS (2014)
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies
Brian D. Harms et al.
METHODS (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
IgGs are made for walking on bacterial and viral surfaces
Johannes Preiner et al.
NATURE COMMUNICATIONS (2014)
Affinity Enhancement of Antibodies: How Low-Affinity Antibodies Produced Early in Immune Responses Are Followed by High-Affinity Antibodies Later and in Memory B-Cell Responses
Herman N. Eisen
CANCER IMMUNOLOGY RESEARCH (2014)
IgG subclasses and allotypes: from structure to effector functions
Gestur Vidarsson et al.
FRONTIERS IN IMMUNOLOGY (2014)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer
Ajay Jain et al.
EUROPEAN JOURNAL OF CANCER (2013)
APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ Receptors
Christian Gieffers et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
Futa Mimoto et al.
MABS (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation
Roger Mueller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Engineered antibody Fc variant with selectively enhanced FcRIIb binding over both FcRIIaR131 and FcRIIaH131
F. Mimoto et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Neutrophils as effector cells for antibody-based immunotherapy of cancer
Marjolein van Egmond et al.
SEMINARS IN CANCER BIOLOGY (2013)
Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12
Yunji Wu et al.
CELL REPORTS (2013)
Back to the future: recombinant polyclonal antibody therapeutics
Xian-zhe Wang et al.
CURRENT OPINION IN CHEMICAL ENGINEERING (2013)
On the roles of polyvalent binding in immune recognition: Perspectives in the nanoscience of immunology and the immune response to nanomedicines
Thomas Vorup-Jensen
ADVANCED DRUG DELIVERY REVIEWS (2012)
Enhanced FcαRI-mediated neutrophil migration towards tumour colonies in the presence of endothelial cells
Marielle A. Otten et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2012)
Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma
Aasia Ghazi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
Frank J. Beurskens et al.
JOURNAL OF IMMUNOLOGY (2012)
Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement
Fubin Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
Nicholas S. Wilson et al.
CANCER CELL (2011)
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII)
Katja Klausz et al.
CANCER SCIENCE (2011)
Antibody-Mediated Coengagement of FcγRIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus
Holly M. Horton et al.
JOURNAL OF IMMUNOLOGY (2011)
Species-Specific Determinants in the IgG CH3 Domain Enable Fab-Arm Exchange by Affecting the Noncovalent CH3-CH3 Interaction Strength
Aran F. Labrijn et al.
JOURNAL OF IMMUNOLOGY (2011)
Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
Ann L. White et al.
JOURNAL OF IMMUNOLOGY (2011)
Functional Characteristics of the High Affinity IgG Receptor, FcγRI
Cees E. van der Poel et al.
JOURNAL OF IMMUNOLOGY (2011)
Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant
Larry Zeitlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcγRIII and antibodies lacking core fucose
Claudia Ferrara et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Markus Kuegler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
Mikkel Wandahl Pedersen et al.
CANCER RESEARCH (2010)
The Human Immune Response to Dengue Virus Is Dominated by Highly Cross-Reactive Antibodies Endowed with Neutralizing and Enhancing Activity
Martina Beltramello et al.
CELL HOST & MICROBE (2010)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Very Few Substitutions in a Germ Line Antibody Are Required To Initiate Significant Domain Exchange
Michael Huber et al.
JOURNAL OF VIROLOGY (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation
Hugo Mouquet et al.
NATURE (2010)
CD20 as a Target for Therapeutic Type I and II Monoclonal Antibodies
Stephen A. Beers et al.
SEMINARS IN HEMATOLOGY (2010)
Few and Far Between: How HIV May Be Evading Antibody Avidity
Joshua S. Klein et al.
PLOS PATHOGENS (2010)
Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
Pierre Bruhns et al.
BLOOD (2009)
Affinity and Avidity in Antibody-Based Tumor Targeting
Stephen I. Rudnick et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2009)
Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity
Akito Natsume et al.
CANCER SCIENCE (2009)
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10
Joshua S. Klein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Structural Difference in the Complement Activation Site of Human IgG1 and IgG3
T. E. Michaelsen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies
Michael Dechant et al.
CANCER RESEARCH (2008)
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
T. Shantha Raju
CURRENT OPINION IN IMMUNOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies
Seung Y. Chu et al.
MOLECULAR IMMUNOLOGY (2008)
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange
Marijn van der Neut Kolfschoten et al.
SCIENCE (2007)
Fc receptor but not complement binding is important in antibody protection against HIV
Ann J. Hessell et al.
NATURE (2007)
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor
Michael Dechant et al.
JOURNAL OF IMMUNOLOGY (2007)
B-cell anergy: from transgenic models to naturally occurring anergic B cells?
John C. Cambier et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Mechanisms controlling production of membrane and secreted immunoglobulin during B cell development
Martha L. Peterson
IMMUNOLOGIC RESEARCH (2007)
Modulation of the effector functions of a human IgG1 through engineering of its hinge region
William F. Dall'Acqua et al.
JOURNAL OF IMMUNOLOGY (2006)
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma
P Macor et al.
CANCER RESEARCH (2006)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions
AM Boruchov et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization
H Wu et al.
JOURNAL OF MOLECULAR BIOLOGY (2005)
Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells
V Groh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma
R Niwa et al.
CANCER RESEARCH (2004)
Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody
MY Zhang et al.
JOURNAL OF VIROLOGY (2004)
B cell antigen receptor signaling 101
JM Dal Porto et al.
MOLECULAR IMMUNOLOGY (2004)
Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy
WK Bleeker et al.
JOURNAL OF IMMUNOLOGY (2004)
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
G Ofek et al.
JOURNAL OF VIROLOGY (2004)
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
DA Calarese et al.
SCIENCE (2003)
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma
MV Dhodapkar et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Design, construction, and in vitro analyses of multivalent antibodies
K Miller et al.
JOURNAL OF IMMUNOLOGY (2003)
Long term maintenance of IgE-mediated memory in mast cells in the absence of detectable serum IgE
S Kubo et al.
JOURNAL OF IMMUNOLOGY (2003)
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody
A Nowakowski et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies
MB Zwick et al.
JOURNAL OF VIROLOGY (2001)
CD40 stimulation accelerates deletion of tumor-specific CD8+ T cells in the absence of tumor-antigen vaccination
RM Kedl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Engineered antibodies with increased activity to recruit complement
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2001)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
分享论文
